ACADIA Pharmaceuticals (ACAD) Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.

Does the media prefer ACAD or VTRS?

In the previous week, Viatris had 23 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 40 mentions for Viatris and 17 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.62 beat Viatris' score of 0.03 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	6 Positive mention(s)	29 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Do analysts rate ACAD or VTRS?

ACADIA Pharmaceuticals presently has a consensus target price of $23.87, suggesting a potential upside of 63.47%. Viatris has a consensus target price of $10.50, suggesting a potential upside of 24.70%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe ACADIA Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Viatris	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Does the MarketBeat Community prefer ACAD or VTRS?

ACADIA Pharmaceuticals received 876 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 73.09% of users gave ACADIA Pharmaceuticals an outperform vote while only 34.85% of users gave Viatris an outperform vote.

Company	Underperform	Outperform
ACADIA Pharmaceuticals	Outperform Votes 899 73.09%	Underperform Votes 331 26.91%
Viatris	Outperform Votes 23 34.85%	Underperform Votes 43 65.15%

Which has stronger earnings & valuation, ACAD or VTRS?

Viatris has higher revenue and earnings than ACADIA Pharmaceuticals. Viatris is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$957.80M	2.54	-$61.29M	$1.36	10.74
Viatris	$14.74B	0.68	$54.70M	-$0.53	-15.89

Is ACAD or VTRS more profitable?

ACADIA Pharmaceuticals has a net margin of 13.83% compared to Viatris' net margin of -5.87%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	13.83%	25.83%	14.71%
Viatris	-5.87%	16.46%	7.09%

Which has more volatility and risk, ACAD or VTRS?

ACADIA Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Do institutionals & insiders believe in ACAD or VTRS?

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

ACADIA Pharmaceuticals beats Viatris on 14 of the 18 factors compared between the two stocks.